Somewhere on almost every peptide website is a sentence doing an enormous amount of load-bearing work: For research use only. Not for human consumption. Sometimes it is in the footer. Sometimes it is a checkbox you tick before checkout. Occasionally it is printed on the vial.
Everyone in the supply chain treats it as a legal firewall. It is not one, and the FDA has now said so in writing to a long list of companies — repeatedly, and recently. Understanding why it fails is more useful than knowing that it does, because the reasoning applies to your marketing too.
The rule the disclaimer runs into
Under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act, an article is a drug if it is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or intended to affect the structure or function of the body.
Intended use is not established by the sentence you would most like to be judged on. The FDA’s intended use regulation directs the agency to objective evidence — your labelling, your advertising, your oral and written statements, the circumstances surrounding distribution, and what you know your customers actually do with the product.
A disclaimer is one piece of evidence. When the rest of the record points the other way, it loses. In practice it does worse than lose, because a disclaimer specifically denying human use, on a product designed and priced and dosed for human use, reads as awareness rather than innocence.
What the FDA actually points at
The recent peptide warning letters are unusually clear about the evidence relied on. Read a few and the same categories recur:
- Benefit language on the product page. Describing a compound as influencing appetite suppression, insulin sensitivity, thermogenesis or fat oxidation is a structure/function claim, whatever heading it sits under.
- “Studied for” and “research suggests” framing. Attributing an effect to a compound is a claim about the compound. Attributing it to a study does not change who is making it.
- Dosing and reconstitution information. Milligram amounts, injection schedules and mixing instructions describe administration to a person.
- What else is in the cart. In a March 2026 letter the agency noted that the site offered bacteriostatic water for injection alongside injectable peptides. Bacteriostatic water exists to reconstitute an injectable for multi-dose human use. Selling it beside the vial answers the intended-use question by itself.
- Customer reviews and testimonials you host. Republishing a customer describing their results is your evidence, on your site.
- Search and social framing. Page titles, meta descriptions and ad copy are statements too.
This is not theoretical, and it is not slowing down
The FDA issued warning letters to peptide sellers through 2025 and into 2026 — including a cluster of them on a single day in March 2026 — covering products from SARMs to retatrutide and tirzepatide. The letters follow a consistent template: the agency reviewed the website, quotes the operator’s own copy back at them, and concludes that the products are unapproved new drugs under sections 505(a) and 301(d), and misbranded under section 502(f)(1) because a prescription drug cannot bear adequate directions for lay use.
Recipients get fifteen working days to respond in writing. The letters state plainly that failure to correct may lead to seizure and injunction.
And warning letters are the soft end. In 2020 a compounding pharmacy pleaded guilty to distributing unapproved new drugs — BPC-157 among them — and forfeited more than $1.7 million. We cover that in peptides in court.
What genuine research use looks like
Research-use-only is a real category. It just does not look anything like a direct-to-consumer storefront.
| Genuine research supply | The consumer gray market |
|---|---|
| Sold to institutions, laboratories and qualified investigators | Sold to anyone with a card, often via social ads |
| Human administration under an IND and IRB oversight | No protocol, no oversight, no investigator |
| No therapeutic benefit claims in marketing | Benefit language is the entire marketing |
| Quantities and formats suited to bench work | Single-patient dosing, injection kits, reconstitution guides |
| No dosing guidance for people | Protocols, cycles, stacks |
If your customer base is patients, you are not supplying research.
If you are the clinic, not the seller
Practices tend to assume that the disclaimer problem belongs to the vendor. It does not stay there.
- Your practice acts independently. Administering an unapproved drug to a patient is the practice’s conduct, and boards discipline licensees for it regardless of what the supplier’s website said.
- Research-grade material is not permitted in human drugs. That labelling asserts the material was not made or released for human administration — no assurance of identity, purity, sterility or endotoxin limits appropriate to injection.
- Insurance is not a backstop. Professional liability policies commonly exclude claims arising from unapproved products or off-label use outside accepted standards. The exclusion tends to be discovered after the claim.
- Consent does not cure it. A patient cannot consent you into compliance. A signed form documents that you told them, which is useful, and it does not change the regulatory status of the article.
The question to ask your supplier
Not “is this legal?” — they will say yes. Ask instead:
- Under what specific authority is this material supplied for administration to patients? Name the section.
- Is the substance on the 503A or 503B bulks list, or a component of an approved drug, or covered by a USP monograph?
- Is the API from a facility registered with the FDA and operating under CGMP? Show me the documentation.
- Will you put answers 1 to 3 in writing on your letterhead?
The last question resolves most of these conversations quickly. Our full list is in the supplier document pack.
Where MDside sits
We do not source research-labelled material for patient administration, and we confirm a supplying pharmacy’s specific authority in writing rather than accepting it by phone. Where a substance has no completed pathway, our providers do not prescribe it.
See how our peptide programs are structured, or read the statutory map underneath all of this.
Related reading
Frequently asked questions
Does “for research use only” protect the seller?
No. Intended use is determined from the whole marketing context, and the FDA has rejected the disclaimer in warning letters to peptide sellers repeatedly through 2025 and 2026. A disclaimer that contradicts the rest of the site tends to be read as evidence of knowledge.
What specifically does the FDA use to prove intended use?
Website copy, benefit and “studied for” language, dosing and reconstitution instructions, customer testimonials, page titles and ad copy, and related products — including selling bacteriostatic water for injection alongside injectable peptides.
Can a clinic buy research-grade peptides if a physician administers them?
A physician’s involvement does not convert an unapproved drug into an approved one, and research-grade material is not permitted in human drugs. The practice carries its own regulatory and licensure exposure independently of the supplier.
What happens after a warning letter?
The recipient has fifteen working days to respond in writing describing corrective action. The letters state that failure to correct may result in seizure or injunction; separately, distribution of unapproved new drugs has supported federal criminal charges.
Is buying peptides for personal research use legal?
Personal purchase is a different question from commercial distribution, and this article is about the latter. What is clear is that the disclaimer does not make the seller’s conduct lawful, and imported unapproved drugs are subject to detention at the border.
General information about FDA intended-use analysis and enforcement practice, not legal advice. Warning letters are summarised from the FDA’s public database; read the letters themselves and consult healthcare counsel about your own marketing.